Lund, Sweden, 16.00 CET, April 16, 2019 – BONESUPPORTTM, an emerging leader in orthobiologics for the management of bone voids, today announced that the quarterly report for the first quarter of 2019 will be published on May 2 at 08.00 CET instead of as previously communicated on 8 May. This is due to the fact that the work on the report has gone faster than previously estimated.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0)708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2020. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information. BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.